Cargando…

Ruxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia

This study aimed to observe the safety and clinical efficacy of early application of ruxolitinib to prevent acute graft-versus-host disease (aGVHD) after alternative donor transplantation in acute leukemia. There were 57 patients undergoing allo-HSCT at the Affiliated Cancer Hospital of Zhengzhou Un...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Binglei, Chen, Lingyun, Zhou, Jian, Zu, Yingling, Gui, Ruirui, Li, Zhen, Wang, Juan, Yu, Fengkuan, Zhang, Yanli, Zhao, Huifang, Ji, Zhenyu, Song, Yongping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8055912/ https://www.ncbi.nlm.nih.gov/pubmed/33875780 http://dx.doi.org/10.1038/s41598-021-88080-3

Ejemplares similares

Metagenomic Next Generation Sequencing in the Detection of Pathogens in Cerebrospinal Fluid of Patients After Alternative Donor Transplantation: A Feasibility Analysis
por: Zhang, Binglei, et al.
Publicado: (2021)

Low-dose PTCy plus low-dose ATG as GVHD prophylaxis after UD-PBSCT for hematologic malignancies: a prospective, multicenter, randomized controlled trial
por: Zu, Yingling, et al.
Publicado: (2023)

Alternative donor peripheral blood stem cell transplantation for the treatment of high-risk refractory and/or relapsed childhood acute leukemia: a randomized trial
por: Zhang, Binglei, et al.
Publicado: (2020)

Selection of hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma
por: Li, Zhen, et al.
Publicado: (2023)

Low-dose post-transplant cyclophosphamide with low-dose antithymocyte globulin for prevention of graft-versus-host disease in first complete remission undergoing 10/10 HLA-matched unrelated donor peripheral blood stem cell transplants: a multicentre, randomized controlled trial
por: Zu, Yingling, et al.
Publicado: (2022)

A retrospective study of autologous hematopoietic stem cell transplantation for peripheral T-cell lymphoma: pre-transplant patients with partial remission benefit from post-transplant maintenance therapy
por: Huang, Zhenghua, et al.
Publicado: (2023)

Feasibility of reduced-dose posttransplant cyclophosphamide and cotransplantation of peripheral blood stem cells and umbilical cord-derived mesenchymal stem cells for SAA
por: Zu, Yingling, et al.
Publicado: (2021)

Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD
por: Liu, Yin, et al.
Publicado: (2022)

Extramedullary relapse of leukemia after allogeneic hematopoietic stem cell transplantation: A retrospective study
por: Xie, Ning, et al.
Publicado: (2019)

Long-Term Use of Ruxolitinib in an AML Patient with Posttransplant Steroid Refractory GVHD
por: Sobash, Philip T., et al.
Publicado: (2020)

Successful outcomes of second hematopoietic stem cell transplantation for graft failure in pediatric patients with severe aplastic anemia
por: He, Meijie, et al.
Publicado: (2022)

The opposite impact of Janus kinase inhibitor Ruxolitinib on the function of bone marrow mesenchymal stem cells and immune cells in acute GVHD recipients
por: Zeng, Defu
Publicado: (2023)

Milestones in acute GVHD pathophysiology
por: Socie, Gerard, et al.
Publicado: (2022)

Efficient treatment of murine acute GvHD by in vitro expanded donor regulatory T cells
por: Riegel, Christin, et al.
Publicado: (2019)

Defibrotide impact on the acute GVHD disease incidence in pediatric hematopoietic stem cell transplant recipients
por: Squillaci, Domenica, et al.
Publicado: (2023)

Donor Bone Marrow-Derived T Cells Inhibit GVHD Induced by Donor Lymphocyte Infusion in Established Mixed Allogeneic Hematopoietic Chimeras
por: Wang, Hui, et al.
Publicado: (2012)

Donor‐derived M2 macrophages attenuate GVHD after allogeneic hematopoietic stem cell transplantation
por: Hanaki, Ryo, et al.
Publicado: (2021)

Concomitant Ruxolitinib and Ibrutinib for Graft-Versus-Host Disease (GVHD): The First Reported Use in Pediatric Patients
por: Gagliardi, Thomas A, et al.
Publicado: (2022)

The utility of biomarkers in acute GVHD prognostication
por: Spyrou, Nikolaos, et al.
Publicado: (2023)

Salvage Therapy With Low-Dose Ruxolitinib Leads to a Significant Improvement in Bronchiolitis Obliterans Syndrome in Patients With cGVHD After Allogeneic Hematopoietic Stem Cell Transplantation
por: Zhao, Yanmin, et al.
Publicado: (2021)

Successful treatment of acute pancreatitis associated with late-onset acute liver GVHD after second allogeneic hematopoietic cell transplantation
por: Hosokawa, Yuka, et al.
Publicado: (2022)

Donor γδT Cells Promote GVL Effect and Mitigate aGVHD in Allogeneic Hematopoietic Stem Cell Transplantation
por: Song, Yuan, et al.
Publicado: (2020)

Chronic GVHD after steroid-sensitive, -dependent, and -refractory acute GVHD: incidence and clinical outcomes
por: Herzog, Shannon, et al.
Publicado: (2023)

Steroid-Refractory Acute GVHD: Predictors and Outcomes
por: Westin, Jason R., et al.
Publicado: (2011)

Letermovir reduces chronic GVHD risk in calcineurin inhibitor-free GVHD prophylaxis after hematopoietic cell transplantation
por: Lorentino, Francesca, et al.
Publicado: (2022)

Endoscopic diagnosis of acute intestinal GVHD following allogeneic hematopoietic SCT: a retrospective analysis in 175 patients
por: Kreisel, W, et al.
Publicado: (2012)

Galectin-3 expression in donor T cells reduces GvHD severity and lethality after allogeneic hematopoietic cell transplantation
por: Mohammadpour, Hemn, et al.
Publicado: (2023)

High incidence of thromboembolism in patients with chronic GVHD: association with severity of GVHD and donor-recipient ABO blood group
por: El Jurdi, Najla, et al.
Publicado: (2021)

Intestinal aGVHD and infection after hematopoietic stem cell transplantation
por: Hou, Cai-yan, et al.
Publicado: (2013)

Ruxolitinib improves hematopoietic regeneration by restoring mesenchymal stromal cell function in acute graft-versus-host disease
por: Lin, Yan, et al.
Publicado: (2023)

Cyclosporine A trough concentrations are associated with acute GvHD after non-myeloablative allogeneic hematopoietic cell transplantation
por: de Kort, Elizabeth A., et al.
Publicado: (2019)

Roles of the intestinal microbiota and microbial metabolites in acute GVHD
por: Lin, Dandan, et al.
Publicado: (2021)

Elevated REG3α predicts refractory aGVHD in patients who received steroids-ruxolitinib as first-line therapy
por: Yang, Jingjing, et al.
Publicado: (2021)

Comparing the application of mNGS after combined pneumonia in hematologic patients receiving hematopoietic stem cell transplantation and chemotherapy: A retrospective analysis
por: Zhang, Binglei, et al.
Publicado: (2022)

Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)
por: von Bubnoff, Nikolas, et al.
Publicado: (2018)

Case Report: Successful engraftment of allogeneic hematopoietic stem cells using CAR-T cell therapy as the conditioning regimen in R/R Ph(+) B cell acute lymphoblastic leukemia
por: Han, Lu, et al.
Publicado: (2022)

Dynamic changes in serum cytokine levels and their clinical significance in predicting acute GVHD
por: Zhang, Chunyan, et al.
Publicado: (2017)

Acute intestinal GVHD following donor-derived CD7-CAR-T-cell infusion in a child with Omicron COVID-19
por: Lian, Yu, et al.
Publicado: (2023)

Effects of aGVHD and cGVHD on Survival Rate in Patients with Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation
por: Shokouhi, Shabnam, et al.
Publicado: (2015)

Blood Stream Infection (BSI) and Acute Graft Versus Host Disease (GVHD) after Hematopoietic Stem Cell Transplantation (HSCT) are Associated
por: Poutsiaka, Debra D, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_eg62blf2nhp2gjtvnkdnps66np